Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) entered a warrant inducement agreement with an existing investor for the immediate cash exercise of November 19, 2025 warrants covering 428,731 shares of common stock at an amended exercise price of $6.00 per share, expected to generate approximately $2.6 million in gross proceeds before fees.
In return, Autonomix Medical will issue the investor unregistered Series D-1 and Series D-2 warrants, each for 428,731 shares, at a $5.75 exercise price, exercisable immediately and expiring five and a half years after issuance. The closing is expected around July 15, 2026, and the company plans to register the resale of shares underlying the new warrants.
Positive
- Approximately $2.6 million expected gross proceeds from warrant exercises before fees
- Immediate cash exercise of 428,731 existing warrants at $6.00 per share
- New Series D-1 and D-2 warrants each exercisable for 428,731 shares at $5.75
Negative
- Issuance of new warrants for up to 857,462 additional shares increases potential future dilution
- Existing November 2025 warrant exercise price amended and reduced to $6.00 per share
News Explained
The
News Market Reaction – AMIX
In the Jul 14 session, AMIX declined 9.74%, reflecting a notable negative market reaction. Argus tracked a peak move of +18.3% during that session. Argus tracked a trough of -30.1% from its starting point during tracking. Our momentum scanner triggered 55 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 150.9x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 13 | IP patent grant | Positive | -12.5% | Grant of Canadian neural sensing patent expanding global IP coverage. |
| Jun 22 | Platform update | Positive | +3.1% | Announcement of standalone neural sensing program with preclinical renal data. |
| Jun 18 | Reverse stock split | Negative | +4.3% | 1-for-21 reverse split reducing outstanding shares while keeping authorization. |
| Jun 10 | Investor communication | Positive | -6.5% | CEO Corner segment highlighting broad scientific and clinical recognition. |
| Jun 04 | Clinical data update | Positive | +3.6% | Presentation and discussion of visceral cancer pain clinical data at SSO meeting. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often produced sharp, sometimes counterintuitive moves, with several positive catalysts met by negative price reactions.
Key Terms
at-the-market financial
form s-3 regulatory
registration statement regulatory
private placement financial
nasdaq rules regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the “November 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding November 2025 Warrants to purchase an aggregate of 428,731 shares of the Company’s common stock at the amended and reduced exercise price of
Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction.
In consideration for the immediate exercise of the existing warrants in cash, the Company also agreed to issue to the Investor unregistered Series D-1 warrants to purchase an aggregate of 428,731 shares of the Company’s common stock, and Series D-2 warrants to purchase an aggregate of 428,731 shares of the Company’s common stock (collectively, the “New Warrants”). The New Warrants will each have an exercise price of
The closing of the warrant exercise transaction is expected to occur on or about July 15, 2026, subject to satisfaction of customary closing conditions.
The New Warrants described above are being offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements include, without limitation, the satisfaction of customary closing conditions related to the warrant transaction and the completion of the warrant transaction. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements, including, but not limited to, the expected completion, timing and size of the warrant transaction, the intended use of proceeds from the transaction and Autonomix’s ability to file a registration statement registering the resale of the securities sold in the transaction. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
